Simple Summary Several anti-angiogenic drugs have been approved for cancer treatment,
alone or in combination with other anti-tumoral agents. Angiogenesis inhibitors cause drug …

Despite substantial advances in the imaging-based diagnosis of renal masses, the
increased detection of incidental renal masses with cross-sectional imaging poses problems …

The MYC oncogene is frequently mutated and overexpressed in human renal cell carcinoma
(RCC). However, there have been no studies on the causative role of MYC or any other …

Renal cell carcinoma (RCC) is a cause of significant morbidity and mortality, with an
estimated 35,000 new cases and 12,480 deaths in the United States in 2003. Recent …

Hypoxia-inducible factor 1α (HIF-1α) plays a critical role in transcriptional gene activation
involved in tumor angiogenesis. A novel class of agents, the histone deacetylase (HDAC) …

The discovery of a relationship for the VHL tumor suppressor gene, hypoxia inducible factor-
1 alpha, and vascular endothelial growth factor in the growth of clear-cell renal cell …

BACKGROUND. In a randomized, phase 3 trial, sunitinib demonstrated superior efficacy
over interferon‐alfa as first‐line therapy in patients with metastatic clear‐cell renal cell …

Renal cell carcinoma (RCC) is the most lethal of the common urologic malignancies, with
approximately 40% of patients eventually dying of cancer progression. Approximately one …

PURPOSE: We assessed the efficacy of the oral multitargeted tyrosine kinase inhibitor
sunitinib in patients with metastatic clear cell renal cell carcinoma. MATERIALS AND …

In clear-cell renal cell carcinoma (ccRCC), inactivation of the tumor suppressor von Hippel–
Lindau (VHL) occurs in the majority of the tumors and is causal for the pathogenesis of …